Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation

IntroductionPrimary infection or reactivation of Epstein-Barr Virus (EBV) is a significant cause of morbidity and mortality in pediatric kidney transplantation. Valganciclovir (VGC) treatment is recommended for prophylaxis of cytomegalovirus infection, but its role for the prevention of EBV infectio...

Full description

Bibliographic Details
Main Authors: Elodie Cheyssac, Hamidou Savadogo, Nathan Lagoutte, Véronique Baudouin, Marina Charbit, Robert Novo, Anne-Laure Sellier-Leclerc, Marc Fila, Stéphane Decramer, Elodie Merieau, Ariane Zaloszyc, Jérôme Harambat, Gwenaelle Roussey
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pediatrics
Subjects:
prophylaxis
pediatric kidney transplantation
valganciclovir
Epstein–Barr virus
PTLD
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.1085101/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.1085101/full

Similar Items